







an Open Access Journal by MDPI

# **Molecular Genetic Investigation of Rare Cancers**

Guest Editor:

#### Dr. Neil Renwick

Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen's University, 88 Stuart St, Kingston, ON K7L 3N6, Canada

Deadline for manuscript submissions:

closed (25 March 2024)

## Message from the Guest Editor

Dear Colleagues,

Rare cancers are defined by their low incidence and prevalence in different populations. However, these cancers collectively account for more than 20 percent of all cancer diagnoses worldwide. Because of their infrequency, rare cancers are often challenging to diagnose, incompletely understood at the molecular level, and lack specific and effective treatments. The unrealistic need for large sample numbers also hampers many clinical studies. In this Special Issue, we focus on genetic, pathobiologic, and computational studies of molecular changes in rare cancer tissues, cell lines, and disease models. We are particularly interested in novel molecular diagnostic, mechanistic, and therapeutic studies. To overcome a major barrier in rare cancer research, well-performed omics-based small case series of n-of-1 studies are particularly encouraged. A fuller understanding of the molecular basis of rare cancers will advance our knowledge of rare cell biology and improve existing diagnostic and therapeutic approaches for these comparatively neglected cancers.













an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

## Message from the Editor-in-Chief

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank: JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))

#### **Contact Us**